Rockwell Medical, Inc 8-K, filed May 23, 2023
Rockwell Medical, Inc. (RMTI)
8-K
2023-05-23
For: 2023-05-23
View Original
Added on
April 10, 2026
About this 8-K
Rockwell Medical, Inc filed this 8-K on May 23, 2023.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 23, 2023
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices, including zip code)
(248 ) 960-9009
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) | ||||||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of Each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 23, 2023, Rockwell Medical, Inc. held its 2023 Annual Meeting of the Stockholders (the "Annual Meeting"). The following matters were submitted to a vote of the stockholders at the Annual Meeting and the voting results were as follows:
Proposal One: To elect the two Class II directors to serve for a three-year term expiring at the 2026 annual meeting of stockholders and until his or her successor has been duly elected and qualified.
| For | Against | Abstain | Broker Non-Votes | ||||||||||||||||||||
| Mark Ravich | 2,015,069 | 873,941 | 36,763 | 4,932,013 | |||||||||||||||||||
| Andrea Heslin Smiley | 2,639,034 | 249,295 | 37,444 | 4,932,013 | |||||||||||||||||||
Proposal Two: To approve, on an advisory basis, the compensation of the Company's named executive officers.
| For | Against | Abstain | Broker Non-Votes | |||||||||||||||||
| 2,485,037 | 337,531 | 103,205 | 4,932,013 | |||||||||||||||||
Proposal Three: To approve, on an advisory basis, the frequency of stockholder advisory votes on compensation of the Company's named executive officers.
| 1 Year | 2 Years | 3 Years | Abstain | Broker Non-Votes | ||||||||||||||||||||||
| 2,704,562 | 69,060 | 95,135 | 57,016 | 4,932,013 | ||||||||||||||||||||||
Proposal Four: To ratify the selection of EisnerAmper LLP as the Company’s independent registered public accounting firm for 2023.
| For | Against | Abstain | ||||||||||||
| 7,696,517 | 119,313 | 41,956 | ||||||||||||
Proposal Five: To approve an amendment and restatement of the Rockwell Medical, Inc. 2018 Long Term Incentive Plan to increase the number of shares reserved for issuance thereunder by 1,600,000 shares.
| For | Against | Abstain | Broker Non-Votes | |||||||||||||||||
| 1,994,126 | 825,079 | 106,568 | 4,932,013 | |||||||||||||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ROCKWELL MEDICAL, INC. | ||||||||
| Date: May 23, 2023 | By: | /s/ Mark Strobeck | ||||||
| Mark Strobeck | ||||||||
| Chief Executive Officer | ||||||||